BioCentury | Oct 4, 2010
Product Development

Dissipating a Slow Torture

While three companies are targeting metabotropic glutamate receptor subtype 5 to treat levodopa-induced dyskinesia, Addex Pharmaceuticals Ltd. was the first to publicly report significant preclinical effects on both the chorea and dystonia components of the...
BC Innovations | Jul 23, 2009
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Addiction Metabotropic glutamate receptor subtype 5 (GRM5; mGluR5); homer homolog 2 (HOMER2); phosphoinositide 3-kinase (PI3K) Studies in mice suggest that inhibiting the mGluR5-HOMER2-PI3K signaling pathway...
Items per page:
1 - 2 of 2